Cjc-1295 dosage

The most reproducible finding across CJC-1295 dosing research is not the milligram amount—it's the frequency. Weekly administration in human trials produces sustained growth hormone pulses comparable to daily dosing of unmodified GHRH analogs, but the dose-response curve remains incompletely mapped above 60 mcg/kg. Published human data clusters tightly around two protocols: 30 mcg/kg weekly and 60 mcg/kg weekly, leaving researchers to extrapolate beyond those bounds.

CJC-1295: A Drug Affinity Complex That Extended GHRH Half-Life 100-Fold

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog engineered to resist enzymatic degradation through two structural modifications. The parent compound is Modified GRF(1-29), a 29-amino acid truncation of native GHRH(1-44) that maintains full receptor activity while removing the N-terminal instability. CJC-1295 adds a drug affinity complex (DAC) side chain—a maleimidoproprionic acid linker attached to lysine at position 15—that binds albumin in circulation.

This albumin binding is the functional innovation. Native GHRH has a plasma half-life under 7 minutes due to rapid cleavage by dipeptidyl peptidase-IV (DPP-IV) at the N-terminus. Modified GRF(1-29) extends this to roughly 30 minutes by substituting D-alanine at position 2, blocking DPP-IV access. The DAC modification in CJC-1295 extends half-life to approximately 6-8 days in humans by creating a circulating albumin-bound reservoir that slowly releases active peptide.

The compound was developed by ConjuChem Biotechnologies in the early 2000s specifically to achieve once-weekly dosing for growth hormone deficiency. It reached Phase II clinical trials before development halted following cardiovascular safety signals in 2010 trials unrelated to the GHRH mechanism itself.

Ipamorelin and other growth hormone secretagogues work through the ghrelin receptor rather than the GHRH receptor, representing a parallel but mechanistically distinct approach to growth hormone elevation.

GHRH Receptor Activation and the Albumin Reservoir Kinetics

CJC-1295 binds the growth hormone-releasing hormone receptor (GHRHR), a class B G-protein coupled receptor expressed predominantly on somatotroph cells in the anterior pituitary. Receptor activation triggers adenylyl cyclase through Gαs coupling, raising intracellular cAMP and activating protein kinase A. This cascade opens voltage-gated calcium channels, triggering fusion of growth hormone storage vesicles with the cell membrane. The result is pulsatile growth hormone secretion into circulation.

The distinguishing pharmacokinetic feature is the DAC-albumin interaction. Once injected subcutaneously, CJC-1295 enters circulation and the maleimidoproprionic acid side chain forms a non-covalent complex with serum albumin. This binding is reversible but has high affinity (Kd in the nanomolar range based on ConjuChem's preclinical characterization). The bound peptide is protected from renal clearance and enzymatic degradation. Dissociation occurs slowly, maintaining a steady concentration of free CJC-1295 available to bind GHRHR over days rather than minutes.

Peak growth hormone response occurs 2-6 hours post-injection in human studies, but importantly, repeated pulses continue for 6-10 days. This distinguishes CJC-1295 from Sermorelin and Mod GRF 1-29, which produce single acute pulses. The albumin reservoir creates a physiological pattern closer to endogenous GHRH secretion—multiple pulses per day—without requiring multiple injections.

Downstream, elevated growth hormone stimulates hepatic IGF-1 production and direct lipolytic effects on adipocytes. Somatotroph desensitization—a concern with sustained GHRH receptor activation—appears minimal in published trials up to 90 days, likely because the peptide preserves pulsatility rather than causing continuous receptor occupancy.

Human Dose-Response Data From Two Controlled Trials

The clearest human dosing data comes from two Phase II studies published by Teichman et al. (2006) in healthy adults and by Ionescu and Frohman (2006) in HIV-associated lipodystrophy. Both used subcutaneous administration and measured growth hormone, IGF-1, and IGFBP-3 as primary endpoints.

In the Teichman study, 30 mcg/kg and 60 mcg/kg doses were compared weekly over 28 days in healthy men aged 21-61. The 30 mcg/kg group showed mean IGF-1 increases of 28.6% above baseline by day 28. The 60 mcg/kg group showed 45.7% increases. Growth hormone area-under-curve increased by approximately 1.5-fold at 30 mcg/kg and 2.0-fold at 60 mcg/kg. Peak growth hormone levels occurred in pulses rather than sustained elevation, and pulsatility was maintained throughout the dosing period.

The Ionescu trial in HIV lipodystrophy used fixed doses rather than weight-based: 0.5 mg, 1.0 mg, or 2.0 mg per injection, administered weekly or biweekly. This translates approximately to 7-30 mcg/kg depending on body weight. Even the lowest dose (0.5 mg weekly) produced statistically significant increases in IGF-1 at 12 weeks. The 2.0 mg weekly dose increased mean IGF-1 by 89 mcg/L, with corresponding reductions in visceral adipose tissue measured by CT.

Notably absent from the literature: dose-response data above 60 mcg/kg in humans, pharmacokinetic characterization beyond 90 days, and head-to-head comparisons against non-DAC Modified GRF(1-29) at equivalent molar doses. No pediatric dosing data exists. Animal studies in rats used 50-200 mcg/kg but pharmacokinetics in rodents differ substantially due to species variation in albumin binding kinetics.

The practical upshot for research purposes only: published protocols converge on 30-60 mcg/kg subcutaneously once weekly. Trials did not identify a clear ceiling dose for efficacy or a minimum effective dose below 30 mcg/kg.

Reconstitution, Stability, and Administration Protocols From Literature

CJC-1295 is supplied as lyophilized powder and requires reconstitution with bacteriostatic water or sterile water for injection. The ConjuChem formulation used bacteriostatic water at a 1:1 ratio (1 mg peptide per mL). Reconstituted solutions in the Teichman study were stored at 2-8°C and used within 7 days.

Stability data from the drug development program indicated the lyophilized powder remains stable for 24 months at -20°C and at least 6 months at room temperature when protected from light. Reconstituted solutions at 4°C maintained >95% peptide integrity for 14 days based on HPLC analysis. Freeze-thaw cycles degraded potency by approximately 10% per cycle, making single-use aliquots preferable for long-term storage.

Administration was subcutaneous in all human trials, most commonly in the abdominal region. Injection site rotation was standard protocol. Absorption kinetics were not formally published, but the drug development documentation suggested peak plasma concentrations occur 1-2 hours post-injection, followed by the albumin-binding phase that establishes the sustained reservoir.

Half-life in humans is reported as 6-8 days based on growth hormone pulsatility data, but this reflects functional half-life of bioactivity rather than peptide clearance half-life. Actual plasma concentration measurements were proprietary to ConjuChem and not published in peer-reviewed literature. For practical reconstitution: a 2 mg vial reconstituted with 2 mL bacteriostatic water yields 1 mg/mL, where a 70 kg individual dosing at 60 mcg/kg would inject 4.2 mg weekly, or 4.2 mL of the reconstituted solution.

GHRP-6 and Hexarelin require daily or twice-daily dosing due to short half-lives, contrasting sharply with CJC-1295's weekly schedule.

Interactions, Suppression, and Desensitization Concerns

Published human trials reported no clinically significant drug interactions, but study populations were generally healthy or had isolated lipodystrophy. Theoretical concerns exist with insulin-sensitizing medications because growth hormone opposes insulin action. Co-administration with metformin or thiazolidinediones was not formally studied but would require glucose monitoring in research contexts.

Endogenous growth hormone suppression—analogous to testosterone suppression with exogenous androgens—was not observed in the Teichman or Ionescu studies. Baseline growth hormone pulsatility returned to pre-treatment levels within 7-14 days of discontinuation. GHRH receptor desensitization, seen with continuous infusions of native GHRH, did not occur at the tested doses. This likely reflects the preserved pulsatility: albumin-bound release maintains the physiological on-off pattern rather than continuous receptor occupancy.

IGF-1 elevations persisted longer than growth hormone pulses, with levels remaining above baseline for 3-6 weeks post-final injection. This reflects the hepatic synthesis lag and IGF-1's longer half-life (12-15 hours). IGFBP-3, the primary IGF-1 binding protein, increased proportionally, which may buffer some peripheral IGF-1 effects.

Antibody formation against CJC-1295 was assessed in extended trials and occurred in fewer than 5% of subjects. Positive antibody titers did not correlate with reduced efficacy or adverse events in the limited follow-up period. Cross-reactivity with native GHRH was not detected. Safety signals that halted Phase III development were related to cardiovascular events in the overall trial population, not mechanistically linked to GHRH receptor activation or antibody formation.

One underreported consideration: CJC-1295's long half-life means dose adjustments or discontinuation decisions require patience. If side effects emerge, the peptide will remain active for approximately two weeks, unlike shorter-acting analogs where effects resolve within 24-48 hours.

FAQ

Q: What is the standard weekly dose of CJC-1295 used in human trials?

Published human trials used 30-60 mcg/kg subcutaneously once per week. The 30 mcg/kg dose produced roughly 28% increases in IGF-1 over 28 days, while 60 mcg/kg produced 45% increases. No studies tested higher doses or alternate schedules systematically.

Q: How does CJC-1295 dosing differ from Ipamorelin or GHRP-6?

CJC-1295 is dosed weekly due to its 6-8 day half-life, while Ipamorelin and GHRP-6 require daily or twice-daily dosing due to half-lives under 2 hours. The compounds also differ mechanistically: CJC-1295 activates the GHRH receptor directly, while growth hormone secretagogues like Ipamorelin work through the ghrelin receptor. They are sometimes combined but act through independent pathways.

Q: Does CJC-1295 suppress endogenous growth hormone production?

The available human data shows no suppression of baseline growth hormone pulsatility during treatment or after discontinuation. Growth hormone levels returned to pre-treatment baselines within 7-14 days of the final injection in published trials. This contrasts with exogenous growth hormone administration, which does suppress endogenous pulsatility through negative feedback.

Q: What happens if someone doses CJC-1295 more frequently than once per week?

No published human data exists for twice-weekly or daily dosing schedules. Given the 6-8 day half-life, more frequent administration would likely cause accumulation and sustained supraphysiological IGF-1 levels rather than preserving pulsatility. The albumin reservoir mechanism is optimized for weekly dosing—more frequent injections would bypass the intended pharmacokinetic design.

Q: How long after reconstitution does CJC-1295 remain stable?

Reconstituted CJC-1295 stored at 2-8°C maintained >95% potency for 14 days based on HPLC analysis from the drug development program. Lyophilized powder is stable for 24 months at -20°C and at least 6 months at room temperature when protected from light. Freeze-thaw cycles degrade potency by roughly 10% per cycle.

CJC-1295 dosing for research applications should follow protocols established in published human trials, recognizing that data above 60 mcg/kg weekly and beyond 90 days of continuous use remains limited. Researchers should note the compound's extended half-life when planning dosing schedules or assessing washout periods between research phases. This article is for informational purposes only and does not constitute medical advice. CJC-1295 is not approved for human use outside of clinical trials. Individuals should consult qualified healthcare providers before participating in any research involving investigational peptides.